1. Home
  2. ODV vs CDNA Comparison

ODV vs CDNA Comparison

Compare ODV & CDNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Osisko Development Corp.

ODV

Osisko Development Corp.

HOLD

Current Price

$3.04

Market Cap

1.1B

ML Signal

HOLD

Logo CareDx Inc.

CDNA

CareDx Inc.

HOLD

Current Price

$16.41

Market Cap

1.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ODV
CDNA
Founded
2005
1998
Country
Canada
United States
Employees
N/A
N/A
Industry
Precious Metals
Medical Specialities
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.1B
1.0B
IPO Year
N/A
2007

Fundamental Metrics

Financial Performance
Metric
ODV
CDNA
Price
$3.04
$16.41
Analyst Decision
Buy
Analyst Count
0
7
Target Price
N/A
$27.33
AVG Volume (30 Days)
2.9M
520.3K
Earning Date
05-05-2026
04-29-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$48,324,000.00
Revenue This Year
$160.81
$16.01
Revenue Next Year
$60.22
$11.31
P/E Ratio
N/A
N/A
Revenue Growth
N/A
18.93
52 Week Low
$1.36
$10.96
52 Week High
$4.80
$21.49

Technical Indicators

Market Signals
Indicator
ODV
CDNA
Relative Strength Index (RSI) 35.90 36.38
Support Level $2.87 $14.09
Resistance Level $3.35 $17.09
Average True Range (ATR) 0.26 0.73
MACD -0.08 -0.01
Stochastic Oscillator 16.56 4.10

Price Performance

Historical Comparison
ODV
CDNA

About ODV Osisko Development Corp.

Osisko Development Corp is a mineral exploration and development company engaged in the acquisition, exploration, and development of precious metals resource properties in North America. The company is focused on exploring and developing its mining assets, including the Cariboo Gold Project in British Columbia, the San Antonio gold project in Mexico, and the Trixie test mine in the USA. The Company manages its business through the exploration, evaluation, and development activities of its projects.

About CDNA CareDx Inc.

CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically the company generates the majority of its revenue from the United States. The company generates the majority of revenue from the Testing services.

Share on Social Networks: